Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1180-1185

  Civitico, Gilda ^a,b   Shaw, Tim ^a   Locarnini, Stephen ^a  

^a FAIRFIELD HOSPITAL   (Australia)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FOSCARNET; GANCICLOVIR; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXICITY; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0029963030     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1180     Document Type: Article

References (42)

1. Angus, P., S. Bowden, M. Richards, J. Ireton, B. Jones, and S. Locarnini. 1993. Combination chemotherapy controls post-liver transplant recurrence of hepatitis, B virus infection. J. Gastroenterol Hepatol. 8:353-357
2. Bain, V. G., H. M. Daniels, A. Chanas, G. J. Alexander, and R. Williams. 1989. Foscarnet therapy in chronic hepatitis B e antigen carriers. J Med. Virol. 29:152-155.
3. Belen'kii, M. S., and R. F. Shinazi. 1994. Multiple drug effect analysis with confidence interval. Antivir. Res. 25:1-11.
4. Bishop, N., G. Civitico, Y. Wang, K. Guo, C. Birch, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic HBV infection. I. Establishment of a suitable in vitro system using the duck hepatitis B virus model. J Med. Virol. 31:82-89
5. Civitico, G., Y. Wang, C. Luscombe, N. Bishop, G. Tachedjian, I. Gust, and S. Locarnini. 1990. Antiviral strategies in chronic hepatitis B virus infection II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled DNA-active compounds. J Med Virol. 31:90-97.
6. Civitico, G. M., and S. A. Locarnini. 1994. The half life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures Virology 203:81-89.
7. Crumpacker, C. S., P. N. Kowalsky, S. A. Oliver. L. E. Sehnipper, and A. K. Field. 1984 Resistance of herpes simplex virus to 9-[(2-hydroxy-1-(hydroxyniethyl)-ethoxy)methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Pioc Natl. Acad. Sci. USA 81:1556-1560.
8. Dean, J., S. Bowden, and S. Locarnini. 1995. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antivir. Res. 27:171-178.
9. Dieterich, D. T., M. A. Poles, E. A. Lew, P. E. Mendez, R. Murphy, A. Addessi, J. T. Holbrook, K. Naughton, and D. N. Friedberg. 1993. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J. Infect Dis. 167:1184-1188.
10. Fautz, R., B. Husein, and C. Heichenberger. 1991. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat Res 253:173-179.
11. Fourel, I., O. Hantz, L. Cova, H. S. Allaudeen, and C. Trepu. 1987. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. Antivir Res. 8:189-199.
12. Frank, K. B., and Y.-C. Cheng. 1985. Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin. phosphonoformate, and acyclic nucleoside triphosphates. Antimicrob. Agents Chemother. 27:445-448.
13. Freitas, V. R., E. Fraser-Smith, and T. Matthews. 1989. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpesvirus type 2 in vitro and in vivo. Antivir. Res. 12:205-212.
14. Ilsley, D. D., S. H. Lee, W. H. Miller, and R. D. Kichta. 1995. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 34:2504-2510.
15. Jilbert, A. R., J. S. Freiman, E. J. Gowans, M. Holmes, Y. E. Cossart, and C. J. Burrell. 1987. Duck hepatitis B virus in liver, spleen and pancreas: analysis by Southern blot hybridization. Virology 158:330-338.
16. Lin, E., C. Luscombe, Y. Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo Antimicrob Agents Chemother. 40:413-418.
17. Locarnini, S. 1991. Design of new antiviral agents for chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 6(Suppl 1):18-22.
18. Locarnini, S. A., K. Guo, C. R. Lucas, and I. D. Gust. 1989. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet ii:1225-1226.
19. Lofgren, B., E. Nordenfelt, and B. Oberg. 1989. Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antivir. Res 12:301-310.
20. Luscombe, C., J. Pederson, S. Bowden, and S. Locarnini. 1994. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 14:182-192
21. Manishewitz, J. F., G. V. Quinnan, Jr., C. Lane, and A. E. Wittek. 1990. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro Antimicrob. Agents Chemother. 34:373-375.
22. Marion, P. 1991. Development of antiviral therapy for chronic infection with hepatitis B virus. Curr. Top. Microbiol. Immunol. 168:167-183.
23. Mason, W. S., J.-M. Lien, D. J. Petcu, L. Coates, W. T. London, A. O'Connell, C. Aldrich, and R. P. Custer. 1987. In vivo and in vitro studies on duck hepatitis B virus replication, p. 3-16 In W. S. Robinson, K. Koike, and H. Will (ed.), Hepadna viruses Alan R. Liss. Inc., New York.
24. McMillan, J. S., T. Shaw, P. W. Angus, and S. A. Locarnini. 1995. Effects of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22:36-43
25. Miller, R. H., and W. S. Robinson. 1984. Hepatitis B virus forms in nuclear and cytoplasmic fractions of infected human liver. Virology 137:390-399.
26. Niu, J., Y. Wang, R. Dixon, S. Bowden, M. Qiao, L. Einck, and S. Locarnini. 1993. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally infected with duck hepatitis B virus. Antivir. Res. 21:155-171
27. Offensperger, W. B., E. Walter, S. Offensperger, C. Zeschnigk, H. E. Blum, and W. Gerok. 1988. Duck hepatitis B virus DNA polymerase: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro Virology 164:48-54.
28. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir Res. 14:181-206.
29. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, N.Y.
30. Seeger, C., J. Summers, and W. S. Mason. 1991 Viral DNA synthesis. Curr. Top. Microbiol. Immunol. 168:41-60
31. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus Antimicrob. Agents Chemother. 38:719-723.
32. Shaw, T., and S. Locarnini. 1995. Hepatic punne and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15:169-184.
33. Sherker, A. H., K. Hirota, M. Omata, and K. Okuda. 1986 Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 91:818-824
34. Smith, K. O., K. S. Galloway, K. K. Ogilvie, and V. O. Cheriyan. 1982. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds. Antimicrob. Agents Chemother 23:113-118.
35. Staschke, K. A., and J. M. Colacino. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol 68:8265-8269.
36. Suhnel, J. 1990 Evaluation of synergism or antagonism for the combined action of antiviral agents. Antivir. Res. 13:23-40.
37. Summers, J., and W. S. Mason. 1982 Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
38. Tuttleman, J. S., J. C. Pugh, and J. W. Summers. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
39. Wang, G.-H., and C. Seeger. 1992. The reverse transcriptase of hepatitis B virus acts ai. a protein primer for viral DNA synthesis. Cell 71:663-670.
40. Wang, Y., S. Bowden, T. Shaw, G. Civitico, Y. Chan, M. Qiao, and S. Locarnini. 1991. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir(9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine). Antivir. Chem. Chemother. 2:107-114.
41. Wang, Y., C. Luscombe, S. Bowden, T. Shaw, and S. Locarnini. 1995. Inhibition of duck hepatitis B virus DNA replication by antiviral therapy with ganciclovir-nalidixic acid Antimicrob. Agents Chemother 39:556-558.
42. Yokata, T., K. Konno, E. Chonan, S. Mochizuki, K. Kojima, S. Shigeta, and E. De Clercq. 1990. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother 34:1326-1330.